Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study

Cachexia is observed in around 60% of patients with extensive-stage small cell lung cancer (ES-SCLC) and may play an important role in the development of resistance to immunotherapy. This study aims to evaluate the influence of cachexia on the effectiveness of immunotherapy, develop and assess a deep learning (DL)-based prediction model for cachexia, as well as its prognostic value.